(A) WT and KO mice (6 weeks old) were immunized with NP-OVA in CFA.
Seven days later, TFR cells
(CD4+CD3+PD-1+CXCR5+YFP+)
were sorted for microarray analysis. Differential gene expression in
TFR from WT and KO mice (>1.5-fold) is shown.
(B) Pathway analysis revealed control of genes associated with
TH cell differentiation by Blimp1.
(C) Genes related to cytokine-cytokine receptor interaction by
DAVID.
(D) IL-23R expression by donor TFR cells in
Tcra−/−
hosts after tamoxifen-induced deletion of Blimp1, as in Figure 4.
(E) IL-23R expression in the CD25-expressing TFR subsets from
WT and KO mice (6–8 weeks old) 10 days post-immunization.
(F) FoxP3-GFP reporter mice were immunized with NP-OVA in CFA. Seven
days later, Treg (CD4+CD3+GFP+CD25+)
and CD4+ naive T cells
(CD4+CD3+GFP−CD44−)
were sorted, chromatin prepared, and ChIP-PCR analyses performed for Blimp1,
acetylated H3 (AcH3), and H3K27me3 at Blimp1-binding sites at the 3rd
intron of Il23r, the 1st intron of
Cxcr5, the 5′ distal element of
CTLA-4, the 3rd intron of Ccr7,
the FoxP3 CNS2, the 1st intron of
Il2ra, and a non-specific region (C, control) of
Il2ra. Data are shown as the percentage of input. Naive
cells were used as controls for the anti-Blimp1 assay. Rabbit IgG isotype
(R-iso) and mouse IgG isotype (M-iso) served as controls for the anti-AcH3 assay
and anti-H3K27 assay, respectively.
(G)
Prdm1fl/fliCre−
(WT) and
Prdm1fl/fliCre+
(Del) mice (8 weeks old) were treated with tamoxifen at day 0, followed by
immunization with NP-OVA in CFA at day 1 and injection of tamoxifen daily for 4
days. Expression of pSTAT3 and pSTAT5 in TFR cells at day 7
post-immunization. At right, pSTAT3:pSTAT5 ratios in TFR cells are
shown (n = 4/group).
In (D), (E), and (G), the data represent one of two experiments. In (F),
the data represent one of three independent experiments. **p < 0.01
(unpaired two-tailed Student’s t test). Error bars indicate means
± SEMs.
See also Figure
S4.